Relationship Between Ultrasound and Physical Examination in the Assessment of Enthesitis in Patients With Spondyloarthritis: Results From the DEUS Multicenter Study (2025)
https://pubmed.ncbi.nlm.nih.gov/39165013/

Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study (2024)
https://pubmed.ncbi.nlm.nih.gov/38443140/

2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases (2024)
https://pubmed.ncbi.nlm.nih.gov/38050029/

Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/36129541/

The DETAIL questionnaire is a useful and effective tool to assess spondyloarthritis in patients with inflammatory bowel disease (2023)
https://pubmed.ncbi.nlm.nih.gov/36844210/

Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases (2023)
https://pubmed.ncbi.nlm.nih.gov/37604639/

Efficacy of pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases (2023)
https://pubmed.ncbi.nlm.nih.gov/38056919/

Predictors of remission in people with axial spondyloarthritis: A systematic literature review (2022)
https://pubmed.ncbi.nlm.nih.gov/35944350/

Reliability assessment of the definition of ultrasound enthesitis in SpA: results of a large, multicentre, international, web-based study (2022)
https://pubmed.ncbi.nlm.nih.gov/35293988/

Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results (2022)
https://pubmed.ncbi.nlm.nih.gov/35088209/

Is the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry (2022)
https://pubmed.ncbi.nlm.nih.gov/33635221/

Predictors of drug retention and treatment response in axial spondyloarthritis patients treated with certolizumab: real-life results from the HURBIO registry (2020)
https://pubmed.ncbi.nlm.nih.gov/31498074/